Literature DB >> 29884797

A novel frameshift deletion in PLS3 causing severe primary osteoporosis.

Alice Costantini1, Panagiotis Ν Krallis2, Anders Kämpe3, Emmanouil M Karavitakis4, Fulya Taylan3, Outi Mäkitie3,5,6,7, Artemis Doulgeraki8.   

Abstract

Mutations in the gene encoding plastin-3, PLS3, have recently been associated to severe primary osteoporosis. The molecular function of plastin-3 is not fully understood. Since PLS3 is located on the X chromosome, males are usually more severely affected than females. PLS3 mutations have thus far been reported in approximately 20 young patients with low bone mineral density (BMD). We describe an 8-year-old Greek boy with severe primary osteoporosis with multiple vertebral compression fractures and one low-energy long bone fracture. His clinical manifestations were consistent with osteogenesis imperfecta, including blue sclerae, joint hypermobility, low bone mineral density, kyphosis, bilateral conductive hearing loss, and mild dysmorphic features. The family history was negative for primary osteoporosis. COL1A1 and COL1A2 mutations were excluded by Sanger sequencing. However, Sanger sequencing of PLS3 led to the identification of a de novo frameshift deletion, NM_005032: c.1096_1100delAACTT, p.(Asn366Serfs*5), in exon 10 confirming the diagnosis of PLS3 osteoporosis. In conclusion, we describe a novel frameshift deletion in PLS3 causing severe primary osteoporosis in a boy. Our finding highlights the clinical overlap between type I collagen and PLS3-related skeletal fragility and underscores the importance of PLS3 screening in patients with multiple fractures to enable proper genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29884797     DOI: 10.1038/s10038-018-0472-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  16 in total

1.  Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation.

Authors:  Denise M van de Laarschot; M Carola Zillikens
Journal:  Bone       Date:  2016-07-29       Impact factor: 4.398

2.  Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics.

Authors:  Somayyeh Fahiminiya; Jacek Majewski; Hadil Al-Jallad; Pierre Moffatt; John Mort; Francis H Glorieux; Paul Roschger; Klaus Klaushofer; Frank Rauch
Journal:  J Bone Miner Res       Date:  2014-08       Impact factor: 6.741

3.  PLS3 Mutations in X-Linked Osteoporosis: Clinical and Bone Characteristics of Two Novel Mutations.

Authors:  Peter Kannu; Areej Mahjoub; Riyana Babul-Hirji; Melissa T Carter; Jennifer Harrington
Journal:  Horm Res Paediatr       Date:  2017-06-12       Impact factor: 2.852

Review 4.  Recent Discoveries in Monogenic Disorders of Childhood Bone Fragility.

Authors:  Riikka E Mäkitie; Anders J Kämpe; Fulya Taylan; Outi Mäkitie
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

5.  Exome sequencing-based identification of mutations in non-syndromic genes among individuals with apparently syndromic features.

Authors:  Eriko Nishi; Koji Masuda; Michiko Arakawa; Hiroshi Kawame; Tomoki Kosho; Masashi Kitahara; Noriko Kubota; Eiko Hidaka; Yuki Katoh; Katsuhiko Shirahige; Kosuke Izumi
Journal:  Am J Med Genet A       Date:  2016-08-26       Impact factor: 2.802

6.  Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy.

Authors:  Gabriela E Oprea; Sandra Kröber; Michelle L McWhorter; Wilfried Rossoll; Stefan Müller; Michael Krawczak; Gary J Bassell; Christine E Beattie; Brunhilde Wirth
Journal:  Science       Date:  2008-04-25       Impact factor: 47.728

7.  PLS3 mutations in X-linked osteoporosis with fractures.

Authors:  Fleur S van Dijk; M Carola Zillikens; Dimitra Micha; Markus Riessland; Carlo L M Marcelis; Christine E de Die-Smulders; Janine Milbradt; Anton A Franken; Arjan J Harsevoort; Klaske D Lichtenbelt; Hans E Pruijs; M Estela Rubio-Gozalbo; Rolf Zwertbroek; Youssef Moutaouakil; Jaqueline Egthuijsen; Matthias Hammerschmidt; Renate Bijman; Cor M Semeins; Astrid D Bakker; Vincent Everts; Jenneke Klein-Nulend; Natalia Campos-Obando; Albert Hofman; Gerard J te Meerman; Annemieke J M H Verkerk; André G Uitterlinden; Alessandra Maugeri; Erik A Sistermans; Quinten Waisfisz; Hanne Meijers-Heijboer; Brunhilde Wirth; Marleen E H Simon; Gerard Pals
Journal:  N Engl J Med       Date:  2013-10-02       Impact factor: 91.245

8.  Osteogenesis imperfecta of the temporal bone and its relation to otosclerosis.

Authors:  G T Nager
Journal:  Ann Otol Rhinol Laryngol       Date:  1988 Nov-Dec       Impact factor: 1.547

9.  Calcium binding is essential for plastin 3 function in Smn-deficient motoneurons.

Authors:  Alison N Lyon; Ricardo H Pineda; le Thi Hao; Elena Kudryashova; Dmitri S Kudryashov; Christine E Beattie
Journal:  Hum Mol Genet       Date:  2013-11-23       Impact factor: 6.150

10.  PLS3 sequencing in childhood-onset primary osteoporosis identifies two novel disease-causing variants.

Authors:  A J Kämpe; A Costantini; R E Mäkitie; N Jäntti; H Valta; M Mäyränpää; H Kröger; M Pekkinen; F Taylan; H Jiao; O Mäkitie
Journal:  Osteoporos Int       Date:  2017-07-26       Impact factor: 4.507

View more
  11 in total

Review 1.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

2.  Osteogenesis imperfecta mutations in plastin 3 lead to impaired calcium regulation of actin bundling.

Authors:  Christopher L Schwebach; Elena Kudryashova; Weili Zheng; Matthew Orchard; Harper Smith; Lucas A Runyan; Edward H Egelman; Dmitri S Kudryashov
Journal:  Bone Res       Date:  2020-05-22       Impact factor: 13.567

Review 3.  Plastin 3 in health and disease: a matter of balance.

Authors:  Lisa Wolff; Eike A Strathmann; Ilka Müller; Daniela Mählich; Charlotte Veltman; Anja Niehoff; Brunhilde Wirth
Journal:  Cell Mol Life Sci       Date:  2021-05-23       Impact factor: 9.261

4.  Identification of the Key Molecular Drivers of Phosphorus Utilization Based on Host miRNA-mRNA and Gut Microbiome Interactions.

Authors:  Siriluck Ponsuksili; Henry Reyer; Frieder Hadlich; Frank Weber; Nares Trakooljul; Michael Oster; Puntita Siengdee; Eduard Muráni; Markus Rodehutscord; Amélia Camarinha-Silva; Jörn Bennewitz; Klaus Wimmers
Journal:  Int J Mol Sci       Date:  2020-04-17       Impact factor: 5.923

5.  Osteogenesis imperfecta mutations in plastin 3 lead to impaired calcium regulation of actin bundling.

Authors:  Christopher L Schwebach; Elena Kudryashova; Weili Zheng; Matthew Orchard; Harper Smith; Lucas A Runyan; Edward H Egelman; Dmitri S Kudryashov
Journal:  Bone Res       Date:  2020-05-22       Impact factor: 13.567

6.  A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta.

Authors:  Jing Hu; Lu-Jiao Li; Wen-Bin Zheng; Di-Chen Zhao; Ou Wang; Yan Jiang; Xiao-Ping Xing; Mei Li; Weibo Xia
Journal:  Mol Genet Genomic Med       Date:  2020-11-09       Impact factor: 2.183

Review 7.  Plastin 3 in X-Linked Osteoporosis: Imbalance of Ca2+-Dependent Regulation Is Equivalent to Protein Loss.

Authors:  Christopher L Schwebach; Elena Kudryashova; Dmitri S Kudryashov
Journal:  Front Cell Dev Biol       Date:  2021-01-21

8.  Structural mechanism for bidirectional actin cross-linking by T-plastin.

Authors:  Lin Mei; Matthew J Reynolds; Damien Garbett; Rui Gong; Tobias Meyer; Gregory M Alushin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-06       Impact factor: 12.779

9.  Expression and Localization of Thrombospondins, Plastin 3, and STIM1 in Different Cartilage Compartments of the Osteoarthritic Varus Knee.

Authors:  Daniela Mählich; Anne Glasmacher; Ilka Müller; Johannes Oppermann; David Grevenstein; Peer Eysel; Juliane Heilig; Brunhilde Wirth; Frank Zaucke; Anja Niehoff
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

Review 10.  Early-Onset Osteoporosis.

Authors:  Outi Mäkitie; M Carola Zillikens
Journal:  Calcif Tissue Int       Date:  2021-07-08       Impact factor: 4.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.